{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-113204","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.912086+00:00","generated_at":"2026-06-22T18:51:14.588976+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiniksa Q3 ARCALYST rev $33.4M, total rev $99.1M, net income $224.1M on tax benefit","bullets":["ARCALYST net revenue $33.4M in Q3 2022; full-year guidance reaffirmed at $115-130M.","Total revenue $99.1M, including $65.7M from vixarelimab license with Genentech.","Net income $224.1M vs net loss $30.5M YoY; includes $177.4M tax benefit from valuation allowance release.","Cash and equivalents $200.7M, no debt; expected to fund operations into at least 2025.","RHAPSODY LTE data: rilonacept beyond 18 months reduced recurrence risk 98.2% (HR=0.018, p<0.0001)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-113204","json":"https://secwatch.observer/filing/0001104659-22-113204.json","markdown":"https://secwatch.observer/filing/0001104659-22-113204.md","text":"https://secwatch.observer/filing/0001104659-22-113204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/0001104659-22-113204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/tm2229208d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T18:51:14.588976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa590154def77fe1ccb26fb2f11366b00aadebc5","claim":"Kiniksa Pharmaceuticals International, plc reported Third Quarter 2022 results: revenue $99.1 million, net income $224.1 million.","evidence_excerpt":"Total revenue for the third quarter of 2022 was $99.1 million, compared to $12.1 million for the third quarter of 2021. - Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST net product revenue and $65.7 million in license and collaboration revenue from the vixarelimab global license agreement with Genentech. Kiniksa did not report license and collaboration revenue in the third quarter of 2021. · Total operating expenses for the third quarter of 2022 were $52.7 million, compared to $42.8 million for the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $4.6 million in collaboration expense. Kiniksa did not report collaboration expense in the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $6.0 million of non-cash, share-based compensation expense, compared to $6.2 million for third quarter of 2021. · Net income for the third quarter of 2022 was $224.1 million, compared to a net lo","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/0001104659-22-113204-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third Quarter 2022"},{"label":"Revenue","value":"$99.1 million"},{"label":"Net income","value":"$224.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}